Henry Ford Health

Henry Ford Health Scholarly Commons
Emergency Medicine Articles

Emergency Medicine

10-1-2022

Acute coronary syndrome prediction in emergency care: A
machine learning approach
Joshua Emakhu
Leslie Monplaisir
Celestine Aguwa
Suzan Arslanturk
Sara Masoud

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/
emergencymedicine_articles

Authors
Joshua Emakhu, Leslie Monplaisir, Celestine Aguwa, Suzan Arslanturk, Sara Masoud, Hashem N.
Nassereddine, Mohamed S. Hamam, and Joseph B. Miller

Computer Methods and Programs in Biomedicine 225 (2022) 107080

Contents lists available at ScienceDirect

Computer Methods and Programs in Biomedicine
journal homepage: www.elsevier.com/locate/cmpb

Acute coronary syndrome prediction in emergency care: A machine
learning approach
Joshua Emakhu a,∗, Leslie Monplaisir a, Celestine Aguwa a, Suzan Arslanturk b, Sara Masoud a,
Hashem Nassereddine c, Mohamed S. Hamam c, Joseph B. Miller c
a
b
c

Department of Industrial and Systems Engineering, Wayne State University, Detroit, MI 48201, USA
Department of Computer Science, Wayne State University, Detroit, MI 48202, USA
Emergency Department, Henry Ford Hospital, Detroit, MI 48202, USA

a r t i c l e

i n f o

Article history:
Received 12 October 2021
Revised 30 July 2022
Accepted 20 August 2022

Keywords:
Acute coronary syndrome
Cost-sensitive classiﬁcation
Electronic health records
Emergency department
Ensemble learning
Non-ST-elevated myocardial infarction

a b s t r a c t
Background and Objective: Clinical concern for acute coronary syndrome (ACS) is one of emergency
medicine’s most common patient encounters. This study aims to develop an ensemble learning-driven
framework as a diagnostic support tool to prevent misdiagnosis.
Methods: We obtained extensive clinical electronic health data on patient encounters with clinical concerns for ACS from a large urban emergency department (ED) between January 2017 and August 2020.
We applied an analytical framework equipped with many well-developed algorithms to improve the data
quality by addressing missing values, dimensionality reduction, and data imbalance. We trained ensemble learning algorithms to classify patients with ACS or non-ACS etiologies of their symptoms. We used
performance evaluation metrics such as accuracy, sensitivity, precision, F1-score, and the area under the
receiver operating characteristic (AUROC) to measure the model’s performance.
Results: The analysis included 31,228 patients, of whom 563 (1.8%) had ACS and 30,665 (98.2%) had
alternative diagnoses. Eleven features, including systolic blood pressure, brain natriuretic peptide, chronic
heart disease, coronary artery disease, creatinine, glucose, heart attack, heart rate, nephrotic syndrome,
red cell distribution width, and troponin level, are reported as signiﬁcantly contributing risk factors. The
proposed framework successfully classiﬁes these cohorts with sensitivity and AUROC as high as 86.3%
and 93.3%. Our proposed model’s accuracy, precision, speciﬁcity, Matthew’s correlation coeﬃcient, and
F1-score were 85.7%, 86.3%, 93%, 80%, and 86.3%, respectively.
Conclusion: Our proposed framework can identify early patients with ACS through further reﬁnement
and validation.
© 2022 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

1. Introduction
Acute coronary syndrome (ACS) is comprised of a spectrum of
diseases categorized by three distinct processes, each with its own
diagnostic and therapeutic challenges: [1] (i) ST-segment elevation
myocardial infarction (STEMI), in which myocardial ischemia results
from total coronary artery occlusion, (ii) Non-ST-segment elevation
myocardial infarction (NSTEMI), in which myocardial ischemia results from partial occlusion, and (iii) Unstable angina (UA), in which
there is dynamic plaque occlusion of the coronary artery placing
patients at high-risk for ischemia.
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Acute coronary syndrome is a leading cause of morbidity and
mortality in developed and developing countries [2]. Clinically, patients with ACS complain of chest pain, occasional radiation to the
arm, jaw, or shoulder, lightheadedness, shortness of breath, nausea,
vomiting, or dyspnea [3]. While these symptoms are common in
emergency department (ED) patients, the diagnosis of ACS remains
challenging [4]. The need to accurately rule out ACS in patients
leads to substantial over-testing that is costly and time-consuming.
[5]
In the past, overestimating the potential for these conditions
has been the standard clinical practice in the emergency department, as increased false-negative results can lead to lifethreatening situations. However, unnecessary tests such as electrocardiography (ECG), cardiac enzyme tests, and long-term hospitalization of patients with chest pain increase the burden of illness
[5]. The clinical diagnosis in the ED of ACS relies on measuring
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cardiac markers, electrocardiogram abnormalities, and patient history [6]. Precise identiﬁcation of patients with coronary artery occlusion or near-occlusion who will beneﬁt from early revascularization can reduce mortality, and accurate identiﬁcation of those
with noncardiac causes of their symptoms can substantially reduce costs and resource utilization. Several risk scores have been
developed for assessing mortality risk in patients with ACS, including the Global Registry of Acute Coronary Events (GRACE) risk
score [7], Acute Coronary Treatment and Intervention Outcomes
Network (ACTION) risk score [8], Thrombolysis in Myocardial Infarction (TIMI) risk score, Canadian ACS risk score [9], and Emergency Department Assessment of Chest Pain Score (EDACS) [10].
While existing risk scoring systems have improved the identiﬁcation of ED patients at high-risk for ACS from noncardiac etiologies,
they sacriﬁce speciﬁcity for high sensitivity.
In their study, Huang, Ying [11], stated that In addition to traditional predictors, self-reported physical activity, average daily heart
rate, ﬂuctuations in arousal blood pressure, and percentage time
of diastolic hypertension contributed signiﬁcantly to the risk classiﬁcation of cardiovascular disease. In a study by [12], they proposed an ensemble that outperforms individual and ensemble classiﬁers in all three datasets containing different feature spaces. In
other words, its generalization ability is excellent. Also, the costs
associated with missing patients (false negatives) are much higher
than those associated with mislabeling (false positives) in healthy
patients. Given the various misclassiﬁcation costs, the proposed
method will be more realistic. They also combined the accuracy
and misclassiﬁcation cost as metrics to allow an ensemble classiﬁer to improve accuracy while reducing misclassiﬁcation cost. According to [13], their study proposed a method that provides a prediction system that detects and critically analyzes vital risk factors
in high-dimensional health data to accurately predict heart disease before a heart attack or stroke occurs. The proposed ensemble deep learning model effectively processes two different data
sources to improve the performance of heart disease diagnosis.
This framework identiﬁes the best features and calculates their
particular importance within the dataset to improve the accuracy
of the predictions.
Mienye, Sun [14] conducted a comparative study using the
Cleveland and Framingham datasets and conducted it with some
recent scientiﬁc papers and other well-known machine learning
algorithms such as k-nearest neighbors (KNN), logistic regression
(LR), linear discriminant analysis (LDA), support vector machines
(SVM), Classiﬁcation and Regression Tree (CART), Gradient Boosting and Random Forest. The experimental results on the dataset
achieved classiﬁcation accuracies of 93% and 91%, respectively,
which outperformed other machine learning algorithms.
Unbalanced datasets present signiﬁcant diﬃculties in terms of
supervised classiﬁcation. Noncardiac etiologies for chest pain are
far more common than ACS, thus leading to an unbalanced dataset
for analysis. Consequently, learning from an unbalanced dataset
is diﬃcult in various practical machine learning (ML) applications
[15]. In addition, class imbalance requires adopting imbalanced analytical approaches such as sampling, machine learning, and ensemble learning [16]. Moreover, although extensive classiﬁcation
studies using unbalanced datasets have been conducted by the ML
and data mining community [17], little or no multi-class ML classiﬁers have been developed for heart disease applications.
Preprocessing techniques are classiﬁed into three groups: (i)
Undersampling techniques produce a subset of the initial dataset
by eliminating certain instances of the majority group. (ii) Oversampling techniques: these produce a superset of the initial dataset
by either duplicating the instances of the minority class or creating new ones using the original minority class instances. (iii) Hybrid methods (Resampling techniques) combine the undersampling
and the oversampling techniques. They are also sensitive to over-

ﬁtting issues; they can dispose of minority class instances by applying oversampling methods to address overﬁtting problems [18].
Data modeling techniques to account for data imbalance problems
signiﬁcantly impact the accuracy of results [19]. The previously
conducted studies showed that sampling techniques and ML algorithms best handle data imbalance streams [20].
A key focus of this study is modeling highly unbalanced tasks
through improved artiﬁcial learning techniques. We use a multistep analysis strategy for modeling imbalanced classiﬁcation problems in stratifying patients with clinical concerns for ACS. This
strategy includes an initial step model of balanced datasets and
a subsequent step that applies and compares ML classiﬁers and
their evaluation performance metrics. This study analyzed the
multi-class classiﬁcation problem using ensemble learning techniques. The fundamental rationale for choosing this approach is
that they are both simple to decipher and effective in solving classimbalance issues [21]. The reality of ACS is that with STEMI, it typically has a straightforward EKG-based diagnosis and does not require further decision support, unlike its other counterparts (i.e.,
NSTEMI and UA), which involves decision support. As a result,
our primary objective was to develop an ensemble, ML multi-class
framework to classify suspected ACS patients into those with ACS
(NSTEMI and UA) or non-ACS etiologies.
2. Methods
The primary purpose of this research is to propose a framework
to classify and distinguish NSTEMI and UA from non-ACS etiologies in the ED. The proposed framework is built on ﬁve phases.
The ﬁrst phase, data preprocessing, involves data cleaning, imputation, transformation, and standardization. The next phase, feature
selection, reduces the dimension of the dataset by identifying the
most suitable features. This leads to the development of a more
reliable model, minimizing the risk of overﬁtting, enhancing accuracy, and reducing the time to train. The third phase handles the
data imbalance by utilizing an integration of cost-sensitive classiﬁcation and resampling techniques. Next, an 80:20 percent train
test split (i.e., 80% training vs. 20%testing) is performed to evaluate the performance of the trained ensemble learning models (i.e.,
Adaptive Boost (AdaBoost), Gradient Boosting, and Extreme Gradient Boosting (XGBoost)) based on several evaluation metrics such
as the AUROC, sensitivity, precision, and F1-score in a robust manner. The ground truth labels (i.e., NSTEMI, UA, and non-ACS etiologies) were established through a panel of adjudicators which is a
mix of cardiologists and emergency physicians.
2.1. Data description
During the study period, we used a private dataset comprising 362,138 patients who visited a large urban ED in the US. The
data records include demographic information, laboratory values,
comorbidities, vital signs, and primary diagnoses coded using the
International Classiﬁcation of Diseases Clinical Modiﬁcation, 10th
Revision (ICD-10-CM). The exclusion criteria for this study consist
of STEMI, transfer from another hospital, and primary residence
outside the state of Michigan. Fig. 2 displays the exclusion criteria of this cohort.
Of the initial 362,138 patients that visited the ED, 330,612 patients are excluded due to unrelated complaints, and 31,526 patients with ACS indications are assessed. 308 STEMI patients are
further excluded from our study due to our focus on NSTEMI, UA,
and non-ACS etiologies. Conclusively, a total of 31,228 patients with
clinical concerns for ACS are selected for this study, of which patients with NSTEMI, UA, and non-ACS etiologies are 431 (1.4%), 132
(0.4%), and 30,665 (98.2%), respectively (Fig. 2).
2
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Fig. 1. Architecture of proposed methodology.

Fig. 2. Selection process for the study cohort.

We understand that the prevalence of ACS accounts for only
about 1.8% of our data. The values are low because, from the data
provided, we are only considering the lower-risk patients without
an initial instance of high troponin levels. These patients do not
immediately rule out NSTEMI or UA by their initial troponin values. So, therefore, by deﬁnition, we are dealing with a lower acuity
group of patients.

technique for identifying pairs of nearest neighbors in a dataset
with different classes. In implementing the resampling techniques,
the idea is to balance the dataset with SMOTE and remove Tomek
links from all classes. This implies that we apply Tomek links to
the oversampled training dataset as a data cleaning approach. Subsequently, we have incorporated the cost-sensitive classiﬁcation, a
multi-class classiﬁcation problem, deﬁned as an associated vector
of costs for labeling each observation under each label. The aim is
to build a classiﬁer that predicts the class with the minimum expected cost. Cost-sensitive classiﬁcation incorporates different costs
of prediction errors into the algorithm when training an ML model
[26]. A cost matrix for each class is deﬁned using the costsensitve
package available in Python to achieve this. It assigns a different
cost for different types of classiﬁcation errors and features of each
observation. At the same time, resampling techniques balance the
data by removing the majority of class instances that form Tomek
links and eliminating instances created by SMOTE [27].

2.2. Data preprocessing
We identiﬁed a broad list of potential clinical features associated with ACS through a review of the medical literature. From
these lists, we selected 58 variables routinely recorded in the electronic health record, including demographic and clinical factors, to
include in the analysis.
2.2.1. Feature engineering
This process involves utilizing domain knowledge to extract features from a record set/dataset. The following stages are performed
during our analysis to achieve the intended objective: (i) One-hot
encoding: replacement of encoded categorical variables with newly
generated binary variables to facilitate better classiﬁcation, as displayed in Fig. 1. (ii) Removing redundant/duplicate data: noise, missing values, and discrepancies capable of adversely impacting the
dataset’s quality and altering the prediction model are present in
our raw dataset. Therefore, duplicate data rows and features having
more than 70% missing values are removed. (iii) Data imputation:
through Multiple Imputations by Chained Equations (MICE) [22].

2.5. Ensemble learning models
Ensemble learning methods are developed by aggregating the
classiﬁcation results of multiple learning algorithms instead of relying upon a single model [28,29]. These models promise better
performance than individually trained ensemble models and provide a robust classiﬁcation due to reducing the variance of the
classiﬁcation error [59]. This study implements three boosting ensemble models with the proposed framework. a) AdaBoost (i.e.,
Adaptive Boosting) tweaks subsequent weak learners to build a robust classiﬁer. Although individual learners can be weak, the ﬁnal
model can be proven to converge into a strong learner [30]. b) Gradient Boosting is an ML technique for regression, classiﬁcation, and
other tasks, which yields a prediction model in the form of an ensemble of weak prediction models, usually decision trees [31,32].
Once a decision tree is a weak learner, the subsequent algorithm is
called Gradient boosted trees, outperforming random forest. c) XGBoost, also known as Extreme Gradient Boosting, is a widely used
ML algorithm for classiﬁcation and regression problems. It implements Gradient boosted decision trees designed for speed and performance [33].

2.3. Feature selection
Feature Selection is the process of streamlining features to only
those contributing the most to the output [23]. BorutaShap is a
wrapper feature selection technique that consolidates the Boruta
[24] feature selection algorithm with the SHAP (SHapely Additive
exPlanations) values [25]. BorutaShap is applied when identifying
the variables with the most contribution to enhancing classiﬁcation performance [20].
2.4. Data balancing (Resampling techniques & cost-sensitive
classiﬁcation)

2.6. Model evaluation
A sequential integration of resampling techniques (i.e., the combination of synthetic minority oversampling technique (SMOTE)
and Tomek links (i.e., SMOTETomek)) and cost-sensitive classiﬁcation is applied to address the data imbalance. Tomek Links is a

The confusion matrix is used to summarize the model’s performance. The performance metrics used in this analysis are as follows:
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tion width (RCDW), and troponin level, are reported as signiﬁcantly
contributing risk factors.
For each identiﬁed feature, a set of ranges is deﬁned based
on the third quartile (i.e., the 75th percentile) and the maximum.
Table 2 shows the selected features and their range of values.
Fig. 4 shows the data imbalance before and after implementing
the resampling technique. Before the data imbalance, NSTEMI, UA,
and non-ACS etiologies are 345, 97, and 24,540 for the training set.
After data balancing, NSTEMI, UA, and non-ACS etiologies’ training
set becomes 24,540, 24,540, and 24,528, respectively.
Fig. 4 shows that the dataset became balanced after implementing the resampling technique on the training dataset (SMOTETomek). The only downside with this is that, with the application of SMOTE, synthetic samples are generated for the minority
classes, which are not as concrete as the majority class, leading
to low precision, sensitivity, and F1-score values. To further address this issue, we implement the cost-sensitive classiﬁcation approach. Hence, the costsensitve package in Python, as discussed in
Section 2, helps determine the optimal cost matrix required to
build a classiﬁer that predicts the class with the minimum expected cost. Table 3 shows the total misclassiﬁcation costs and associated accuracies based on the boosting ensemble models.
From Table 3, we can conclude that the higher the misclassiﬁcation cost, the lower the accuracy. We can justify this statement because, in cost-sensitive learning, each instance is assigned
a misclassiﬁcation cost instead of correctly or incorrectly classiﬁed.
Thus, the problem is to minimize the total misclassiﬁcation cost
instead of optimizing the accuracy.
The proposed framework uses SHAP values to extract feature
importance. When a classiﬁer makes a speciﬁc prediction based
on a set of features, it calculates the performance change with and
without the presence of each feature. Those features leading to a
signiﬁcant performance reduction with their absence will be assigned a higher contribution score. Fig. 5 shows the SHAP values
attributed to the boosting ensemble learning used. Each point represents a sample in training set along with their SHAP scores. The
variables are ranked in descending order, i.e., the troponin level
has the highest feature importance, and a history of chronic heart
disease has the lowest importance. The horizontal location depicts
whether the effect of that value is associated with either a high
or low predictive value. For instance, for the XGBoost model, a
high “troponin” level has a high and positive impact on the type
of primary diagnosis for the patients. The “high” stems from the
red color, and the “positive” impact is depicted from the horizontal
axis. Similarly, we can conclude that “heart rate” negatively correlates with the target variable.
From our proposed approach, we can see that the Gradient
Boosting model outperformed the other ensemble models. The AUROC curve for the three boosting ensemble models is illustrated in
Fig. 6.

Fig. 3. Selection of potential variables by BorutaShap.

•

•

•

•

•

•

•

True Positive (TP) and True Negative (TN): A true positive occurs where the model effectively predicts the positive class.
Likewise, a true negative occurs where the model accurately
predicts the negative class.
False Positive (FP) and False Negative (FN): A false positive occurs where the model ineffectively predicts the positive class.
Likewise, a false negative occurs where the model inaccurately
predicts the negative class.
Accuracy: The accuracy of a model is characterized as the total
number of patients with heart disease divided by the overall
number of patients.
Precision: Precision is used to decide how many have heart disease out of the number of patients predicted to have heart disease.
Sensitivity: Sensitivity is used to decide how many heart disease patients got a positive test result out of the number of
heart disease patients.
Speciﬁcity: Speciﬁcity is used to decide, out of the number of
patients who do not have heart disease, how many got a negative test result.
Matthew’s Correlation Coeﬃcient (MCC): It signiﬁes the prediction ability with values between [–1, +1]. If the estimation of
the MCC classiﬁer is +1, this implies the classiﬁer predictions
are ideal. –1 demonstrates that the classiﬁers produced wrong
predictions. It is characterized as

MCC =



TP × TN − FP × FN

(T P + F P ) (T P + F N ) (T N + F P ) (T N + F N )

3. Results
Table 1 shows the baseline characteristics of our dataset (i.e.,
patients with NSTEMI, UA, or non-ACS etiologies), where all measurable tests have a signiﬁcance level of 5%. The age 64.36± 2.03
represents a mean of 64.36 and a standard deviation of 2.03. The
dominance of atrial ﬁbrillation (37% vs 7.6% vs 7.4%), congestive
heart failure (31% vs 28% vs 19%), chronic heart failure (37% vs 34%
vs 18%), chronic kidney disease (30% vs 22% vs 25%), cardiovascular disease (58% vs 56% vs 33%), heart attack (35% vs 13% vs 4.7%),
and obesity (17% vs 14% vs 15%) are observed more dominantly in
NSTEMI patients is represented in Table 1.
Fig. 3 shows the contributions of each feature towards prediction through BorutaShap, where the green, yellow, and red bars
represent accepted, tentative, and rejected features, respectively. A
total of 11 features, including systolic blood pressure, brain natriuretic peptide (BNP), chronic heart failure (CHF), coronary artery
disease (CAD), creatinine, glucose, history of myocardial infarction
(i.e., heart attack), heart rate, nephrotic syndrome, red cell distribu-

4. Discussion
To study the signiﬁcance of different steps in our proposed algorithm, we trained predictive models on raw data, transformed
data via cost-sensitive classiﬁcation and feature selection, and
transformed data via cost-sensitive classiﬁcation and feature selection and resampling, as displayed in Table 4. Table 4 shows the
performance comparison of the models used at different levels of
data processing. Although all models display a relatively high average accuracy score of 97.7% on raw data, they lack precision and
sensitivity, leading to a very low F1-score due to low precision and
sensitivity. This is caused by the data imbalance where the models
learn classiﬁcation of every data point as non-ACS, providing an
average accuracy of 97.7% as the dataset is heavily biased toward
the non-ACS patients given that 30,655 out of 31,228 patients (i.e.,
4
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Table 1
Baseline characteristics of selected features.
Variables

NSTEMI(N = 431)

UA(N = 132)

Non-ACS(N = 30,665)

p-value

Age
Sex
Female (%)
Male (%)
Ethnicity
Decline (%)
Do not know (%)
Hispanic/Latino (%)
Not Hispanic/Latino (%)
On treatment for hypertension (%)
Abdominal aortic aneurysm (%)
Atrial ﬁbrillation (%)
Anemia (%)
Asthma (%)
Breast cancer (%)
Coronary artery disease (%)
Congestive heart failure (%)
Chronic heart failure (%)
Chronic liver disease (%)
Chronic lung disease (%)
Chronic kidney disease (%)
Chronic obstructive pulmonary disease (%)
Cardiovascular disease (%)
Diabetes (%)
Type-2 diabetes (%)
Hypertension (%)
History of hemoglobinopathies (%)
Lipid disorder (%)
Nephrotic syndrome (%)
Noncardiac atherosclerosis (%)
Peripheral vascular disease (%)
Heart attack (%)
Liver disease (%)
CAD risk factors (%)
Obesity (%)
Systolic blood pressure
Diastolic blood pressure
Heart rate
Temperature
Respiratory rate
Oxygen saturation
Troponin
Brain natriuretic peptide
Red blood cell
White blood cell
Platelet count
Hematocrit
Hemoglobin
Mean corpuscular hemoglobin
Mean corpuscular hemoglobin concentration
Mean corpuscular volume
Red cell distribution width
Anion
Blood urea nitrogen
Calcium
Glucose
Chlorine
Carbon dioxide
Creatinine
Potassium
Sodium
Glomerular ﬁltration rate
Glomerular ﬁltration rate Non-African American

64.36± 2.03

60.05± 0.62

59.11± 0.01

<0.001

48
52

42
58

53
47

N/A

2
1
3
94
65
1
37
20
5
1
54
31
37
5
20
30
15
58
30
32
60
–
–
1
–
11
35
69
68
17
147± 1.85
85± 0.83
87± 1.01
98± 0.01
20± 0.07
97.03± 0.05
2.39± 0.01
610.43± 1873.44
4.38± 0.00
8.96± 0.10
234.27± 61.92
38.48± 0.10
12.36± 0.01
29.00± 0.0
32.84± 0.00
88.21± 0.14
15.38± 0.02
9.11± 0.11
9.73± 0.00
9.30± 0.00
137.50± 77.98
103.11± 0.06
23.52± 0.04
1.82± 0.01
4.22± 0.00
137.09± 0.04
69.72± 2.82
60.37± 2.4

–
–
4
96
73
2
8
18
8
–
61
28
34
8
24
22
19
57
38
40
61
–
–
–
–
11
13
78
76
14
140± 6.03
79± 2.71
77± 3.29
98± 0.03
19± 0.22
97.93± 0.15
0.06± 0.02
160.71± 6238.75
4.44± 0.00
7.25± 0.30
224.74± 19.28
38.53± 0.31
12.78± 0.04
28.90± 0.07
33.10± 0.01
87.25± 0.46
15.04± 0.05
10.47± 0.04
23.69± 0.00
9.31± 0.00
164.92± 24.16
104.21± 0.06
24.08± 0.13
1.36± 0.03
4.08± 0.01
137.39± 0.13
81.16± 9.24
70.48± 7.69

2
1
5
92
51
1
7
21
10
1
13
19
18
7
22
26
15
33
25
26
48
–
–
–
–
5
5
72
58
15
138± 0.03
81± 0.01
88± 0.01
98± 0.00
20± 0.00
97.22± 0.00
0.10± 0.00
397.61± 35.87
4.29± 0.00
8.40± 0.00
232.03± 0.27
37.46± 0.00
12.31± 0.00
28.85± 0.00
32.81± 0.00
87.80± 0.00
15.56± 0.00
9.73± 0.00
21.62± 0.01
9.27± 0.00
134.73± 0.34
102.87± 0.00
24.35± 0.00
1.60± 0.00
4.14± 0.00
139.95± 0.00
78.49± 0.04
69.03± 0.03

N/A

98.2%) are suffering from non-ACS. This leads to signiﬁcant false
positive and false negative classiﬁcations and results in low precision (i.e., 47.7%), sensitivity (i.e., 43.0%), F1-score (i.e., 43.3%), and
MCC (i.e., 13.7%). Although we had good speciﬁcity (i.e., 74.0%).
where: CSC – Cost-sensitive classiﬁcation, FS – Feature selection,
and RS – Resampling
As shown in Table 4, feature selection and cost-sensitive classiﬁcation combined led to a minor increase in the average accuracy,

<0.001
<0.001
<0.001
0.847
0.021
0.121
0.000
<0.001
0.005
0.019
0.246
<0.001
<0.001
0.615
0.015
0.393
0.022
<0.001
0.022
0.418
<0.001
0.009
<0.001
0.039
0.104
0.374
<0.001
<0.001

precision, MCC, and F1-scores by 0.3%, 0.3%, 1.0%, and 0.4%, respectively. It only reduced the sensitivity and speciﬁcity scores by 1.3%
and 0.7%, respectively. Finally, our proposed model (i.e., the combination of feature selection, cost-sensitive classiﬁcation, and resampling) does reduce the average accuracy score by 12.2%. Still,
it also improves the average precision, sensitivity, speciﬁcity, MCC,
and F1-scores by 38.6%, 43.3%, 19%, 66.3%, and 43%, respectively.
Also, the MCC scores for the raw data and transformed data via
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Fig. 4. Data distribution of the training set before and after resampling.

Fig. 5. SHAP values for Adaboost, Gradient Boosting, and XGBoost, respectively.

Fig. 6. ROC for XGBoost, Gradient Boosting, and AdaBoost, respectively.

Table 2
Range of continuous variables independently associated with NSTEMI.

Table 3
Misclassiﬁcation cost and accuracy for the chosen cost matrix.

Features

Range of Values

Unit

Boosting Models

Total Misclassiﬁcation Cost

Accuracy (%)

Brain Natriuretic Peptide
Creatinine
Glucose
Heart Rate
Red Cell Distribution Width
Systolic Blood Pressure
Troponin

200 – 555
1.3 – 1.8
160 – 225
95 – 137
15.6 – 18.6
130 – 210
0.4 – 1.00

pg/mL
mg/dL
mg/dL
beats per minute
%
mmHg
ng/mL

AdaBoost (ADB)
Gradient Boosting (GRB)
XGBoost (XGB)

7683.60
3521.35
4586.46

79
90
88

False Positives are crucial. Also, given that we applied an oversampling technique to our data, it puts more weight on the smaller
classes, making the model biased. The model will now predict the
smaller classes with higher accuracy, but the overall accuracy will
decrease.

the combination of FS + CSC based on the XGBoost model have no
record due to its negative value.
Since we are initially dealing with a framework of imbalanced
datasets, accuracy automatically becomes an improper measure
since it cannot distinguish between the numbers of correctly classiﬁed examples of different classes. Thus, measures like F1-score
become more favorable in this case, as the False Negatives and

4.1. Main ﬁndings
Our current study ﬁndings show that the Gradient Boosting
model can correctly identify NSTEMI from UA and non-ACS etiologies using clinical data. The key ﬁndings are (1) Our proposed
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Table 4
Performance comparison of the boosting ensemble.
Data Processing Levels

Boosting Ensemble Model

Accuracy (%)

Precision (%)

Sensitivity (%)

Speciﬁcity (%)

F1-score (%)

MCC (%)

AUROC (%)

Raw Data

ADB
GRB
XGB

97.0
98.0
98.0
97.7
98.0
98.0
98.0
98.0
79.0
90.0
88.0
85.7

41.0
50.0
52.0
47.7
45.0
51.0
54.0
50.0
80.0
91.0
88.0
86.3

48.0
41.0
40.0
43.0
45.0
41.0
39.0
41.7
80.0
91.0
88.0
86.3

77.0
73.0
72.0
74.0
76.0
73.0
71.0
73.3
90.0
95.0
94.0
93.0

43.0
44.0
43.0
43.3
45.0
44.0
42.0
43.7
80.0
91.0
88.0
86.3

21.0
20.0
–
13.7
24.0
20.0
–
14.7
71.0
86.0
83.0
80.0

98.0
100.0
100.0
99.3
99.0
100.0
100.0
99.7
85.0
98.0
97.0
93.3

Average
FS + CSC

Average
Proposed Framework
(FS + CSC+ RS)

ADB
GRB
XGB
ADB
GRB
XGB

Average

framework delivers a good performance level with an AUROC score
and F-1 score of 98% and 91%, respectively, and (2) identiﬁcation of
clinical features using BorutaShap. Using BorutaShap, we identiﬁed
eleven signiﬁcant predictors: BNP, CHD, CAD, creatinine, glucose,
heart attack, heart rate, nephrotic syndrome, RCDW, SBP, and troponin were independently associated with NSTEMI. However, the
accuracy, sensitivity, speciﬁcity, MCC, and F1-score of the Gradient
Boosting model were 90%, 91%, 95%, 86%, and 91%, respectively.

4.4. Strengths
Our ﬁndings show that ML can effectively diagnose and distinguish between NSTEMI, UA, and noncardiac chest pain given in
the clinical data. The proposed framework can accurately classify
these diseases and identify the top features that signiﬁcantly contribute to the classiﬁcation process. As per a review of the literature, this is the ﬁrst study to develop a support framework to diagnose NSTEMI, UA, and non-ACS etiologies based on clinical data
alone. Though our proposed framework shows high accuracy, precision, sensitivity, and AUROC scores, incorporating clinical notes
(e.g., treating physician’s comments) may further improve the performance of our proposed framework.

4.2. Clinical implications
In current clinical settings, ACS diagnosis in patients with nonST elevations is diﬃcult [34]. Incorrect diagnosis of a patient with
ACS is associated with signiﬁcant morbidity and mortality. Consequently, the overdiagnosis of these patients leads to unnecessary
testing, eventually leading to a rise in medical care costs. Due to
its high sensitivity and precision, our proposed framework can potentially improve the existing standard of care. Current diagnostic
tools may fail to meet expectations in diagnosing NSTEMI patients
as their diagnostics depend primarily on serum troponin levels and
patient histories. We reason that the proposed framework can allow clinicians to improve patient outcomes through more accurate and timely diagnoses. It can also assist physicians with decisions regarding additional treatments and longer lengths of stay.
Our proposed framework can offer a chance for ﬁnancially savvy
diagnostics as physicians can rely on a broader range of symptoms
to accurately identify patients with NSTEMI, UA, and non-ACS etiologies.

4.5. Limitation
In addition, the proposed framework has not been implemented
in actual clinical practice yet. The potential variable will likely upgrade clinical dynamics and improve targeted patient wellbeing.
5. Conclusion
Our ﬁndings support that our proposed model may enable us to
identify signiﬁcant variables and diagnose NSTEMI, UA, and nonACS with high accuracy and sensitivity. These outcomes will likely
change the way ACS patients are currently diagnosed and will
aid in minimizing the risk attributed to the development of lifethreatening STEMI. There is an extremely high risk of a major adverse cardiovascular event in wrongly diagnosed stable NSTEMI patients. Early diagnosis of stable NSTEMI and UA has a massive clinical incentive for the choices involved in managing these diseases
(such as an early invasive strategy like angiography and cardiac
revascularization with percutaneous coronary intervention). Our
study uses single-center data to develop a diagnostic decision support tool. Nonetheless, this proposed tool would help drive toward
customized medicine and better risk management for NSTEMI, UA,
and non-ACS etiologies patients with clinical concerns for ACS.
For our future research, we plan on spatiotemporally validating this on external data to address the generalizability of our proposed framework. Also, we would like to see what effect clinical
narratives from physicians’ comments have on our classiﬁcation
model. Furthermore, other research areas may include better application of image data obtained during laboratory visits to improve
decision support for these groups of ACS patients.

4.3. Interpretation of predictors
In this study, the feature selection process merged data-driven
systems and domain knowledge, ensuring a comprehensive selection of clinical variables. From the literature, several risk factors, such as elevated troponin, history of myocardial infarction
(i.e., heart attack), and coronary artery disease, are exceptionally associated with NSTEMI [35,36], thus supporting the performance of the proposed framework. This study also showed that
troponin strongly indicates NSTEMI cases [37–39]. Additionally,
chronic heart disease, elevated creatinine, coronary artery disease,
history of myocardial infarction (i.e., heart attack), and high systolic blood pressure were considered solid indicators of NSTEMI
case prediction [40–42]. Furthermore, nephrotic syndrome and elevated glucose, BNP, and RCDW are distinguished indicators in our
study. Then, a hybrid combination of resampling techniques and
cost-sensitive classiﬁcation addresses the data imbalance. Finally,
the ensemble model showed high accuracy, sensitivity, and precision. The models also exhibited extraordinary ingenuity in classifying NSTEMI from UA and non-ACS etiologies.
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